The reversal of low-molecular-weight heparin (LMWH) and the management of bleeding patients on LMWH remain highly challenging. Even if LMWH is very extensively administered in the prophylaxis and treatment of venous thrombosis, specific antidotes are lacking, and reversal strategies have very weak grade of evidences on clinical effectiveness. We here describe a reversal strategy with protamine and FVIIa in a patient presenting with hemorrhagic shock and cardiocirculatory arrest.
The challenge of hemorrhagic shock management during low-molecular-weight heparin treatment
Morotti A.
First
;Branca E.;Guerrasio A.Last
2020-01-01
Abstract
The reversal of low-molecular-weight heparin (LMWH) and the management of bleeding patients on LMWH remain highly challenging. Even if LMWH is very extensively administered in the prophylaxis and treatment of venous thrombosis, specific antidotes are lacking, and reversal strategies have very weak grade of evidences on clinical effectiveness. We here describe a reversal strategy with protamine and FVIIa in a patient presenting with hemorrhagic shock and cardiocirculatory arrest.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
jbm-232109-the-challenge-of-hemorrhagic-shock-management-during-low-mol (1).pdf
Accesso aperto
Tipo di file:
PDF EDITORIALE
Dimensione
229.65 kB
Formato
Adobe PDF
|
229.65 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
